Metopimazine Viatris Conseil (Metopimazine)

Metopimazine works by selectively blocking dopamine D2 receptors in the chemoreceptor trigger zone and the gastrointestinal tract. This antagonism reduces the neural signals that trigger the vomiting reflex, thereby providing effective control of nausea and vomiting.

The appropriate dose of Metopimazine is determined by the prescribing healthcare professional based on the patient’s condition, age, weight, and response to therapy. No fixed regimen is provided here; the prescriber will set the dosage and schedule.

Safety data for Metopimazine during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metopimazine belongs to the phenothiazine class, whereas many alternatives such as ondansetron are serotonin 5‑HT3 antagonists. Phenothiazines primarily block dopamine receptors, which can be advantageous in dopamine‑mediated nausea, but they may have a higher incidence of extrapyramidal side effects compared with 5‑HT3 agents.

Metopimazine tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

Metopimazine is administered orally. The tablet should be swallowed whole with a glass of water, preferably on an empty stomach unless otherwise directed by the prescriber. Do not crush or chew the tablet unless instructed.

Serious risks include extrapyramidal reactions such as dystonia or akathisia, neuroleptic malignant syndrome, severe hypotension, and cardiac arrhythmias. Patients should be monitored for these events, and any sudden or severe symptoms should prompt immediate medical evaluation.

Metopimazine is contraindicated in individuals with known hypersensitivity to phenothiazine derivatives. Caution is also advised for patients with severe hepatic or renal impairment, uncontrolled cardiac disease, or a history of severe extrapyramidal disorders.